Abstract | OBJECTIVE: METHODS: Integrated analyses were made of 8-week, randomized, double-blind, placebo-controlled phase 2 clinical trials involving 250 men with mild-to-severe erectile dysfunction of various etiologies who received aildenafil citrate 30 or 60 mg (n = 167) or placebo (n = 83). RESULTS: The statistic results of International Index of Erectile Function, Patient Sexual Encounter Profile (SEP) diaries and Global Assessment Question (GAQ) were significantly higher in the aildenafil citrate patients than in the placebo controls. The main drug-related adverse events were flushing, headache, dizziness and naupathia, which were mild and could be self-relieved. CONCLUSION:
|
Authors | Zhan-ju He, Kai Zhang, Jie Jin, Ning-chen Li, Yan-qun Na, Wen-jun Bai, Xiao-feng Wang, Ji-chuan Zhu, Hui Jiang, Ren-pei Yuan, Bao-fa Hong, Tao Song, Yong Yang, Dong-xi Dai |
Journal | Zhonghua nan ke xue = National journal of andrology
(Zhonghua Nan Ke Xue)
Vol. 12
Issue 12
Pg. 1080-3
(Dec 2006)
ISSN: 1009-3591 [Print] China |
PMID | 17201251
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphodiesterase Inhibitors
- Piperazines
- Sulfones
- aildenafil
|
Topics |
- Administration, Oral
- Double-Blind Method
- Drug Administration Schedule
- Erectile Dysfunction
(drug therapy)
- Humans
- Male
- Phosphodiesterase Inhibitors
(adverse effects, therapeutic use)
- Piperazines
(adverse effects, therapeutic use)
- Sulfones
(adverse effects, therapeutic use)
- Treatment Outcome
|